Patient, if not long-suffering, shareholders in Rochester Medical (ROCM) finally got their vindication on Wednesday, as Bard (BCR)
stepped up with an all-cash offer for this largely home-care focused
urology devices company. Although this deal is not going to radically
change the growth outlook for Bard, it is a logical buy-vs-build move
that should add long-term value and give the company entry into a market
that should be poised for growth in the coming years.
Please continue here:
Home Is Where The Bard Is
No comments:
Post a Comment